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Abstract 
Testosterone supplementation is commonly used for its effects on sexual function, bone health 
and body composition, yet its effects on disease outcomes are unknown. To better understand 
this, we identified genetic determinants of testosterone levels and related sex hormone traits in 
425,097 UK Biobank study participants. Using 2,571 genome-wide significant associations, we 
demonstrate the genetic determinants of testosterone levels are substantially different 
between sexes, and that genetically higher testosterone is harmful for metabolic diseases in 
women but beneficial in men. For example, a genetically determined 1-standard deviation 
higher testosterone increases the risks of Type 2 diabetes (T2D) (OR=1.37 [1.22–1.53]) and 
polycystic ovary syndrome (OR=1.51 [1.33–1.72]) in women, but reduces T2D risk in men 
(OR=0.86 [0.76–0.98]). We also show adverse effects of higher testosterone on breast and 
endometrial cancers in women, and prostate cancer in men. Our findings provide insights into 





The role of testosterone in disease is largely unknown, despite its strong epidemiological 
correlations with many health conditions and the widespread use of testosterone supplements. 
Previous studies have shown protective effects of testosterone on T2D and related metabolic 
traits in men, but harmful effects in women1,2. However, such phenotypic observations are 
prone to confounding due to the substantial effects of ageing and adiposity on circulating 
testosterone concentrations3.  
More than 3% of US men aged 30 years or older received a prescription for testosterone in 
2013, just prior to a US Food and Drug Administration safety communication on its possible 
cardiovascular risks4, and rates of prescribing are even higher in Canada5.  Testosterone therapy 
has established positive effects in randomised controlled trials on sexual function, lean mass, 
muscle strength and bone mineral density, and reductions in whole body and intra-abdominal 
fat6. These body composition changes should predict benefits of testosterone on T2D and 
cardio-metabolic disease. Conversely, testosterone is known to promote growth and metastasis 
of prostate cancers and observational studies have shown that testosterone replacement 
therapy might increase susceptibility to future prostate cancer7–9. However, even the largest 
trials of testosterone have too few cases of incident T2D, cardio-vascular disease (CVD) or 
prostate cancer to provide informative data on these risks10. Furthermore, experimental studies 
of testosterone therapy in men, with or without T2D, surprisingly report no or modest 
improvements in insulin sensitivity and no change in glycaemic control11,12. Similarly, in women, 
experimental evidence of testosterone administration is insufficient to confirm the apparently 
metabolically harmful associations in observational studies between testosterone and higher 
adiposity, risk of polycystic ovary syndrome (PCOS) and other CVD risk markers13,14.  
Mendelian randomisation is a genetic approach to understand the causal effects of putative risk 
factors on disease. Given alleles are both randomly assigned and fixed at conception, genetic 
risk can be used as an epidemiological exposure to reduce the effects of confounding and 
reverse causality. Previous studies have used this approach to test the role of sex hormones in 
disease, but were largely limited to cis variants in the sex-hormone binding globulin (SHBG) 
protein-coding gene. Such studies reported that SHBG-raising alleles were associated with 
lower risk of T2D, but did not test effects separately in men and women15,16. Furthermore, 
because higher SHBG reduces levels of bioavailable testosterone, separation of the apparent 
effects of testosterone from those of SHBG on disease is a major challenge. 
To identify additional genetic variants that can be used to test the effects of testosterone, large 
genome wide association studies (GWAS) are needed. Previous GWAS for sex hormone levels in 
men and women were small17–20, identifying only a handful of associated loci. This study 
substantially advances our understanding of the genetic regulation of sex hormone levels, 
increasing the number of known genetic determinants by two orders of magnitude. We use 
these genetic variants to demonstrate likely causal associations with metabolic disease and 
cancer outcomes, with many divergent effects of testosterone between men and women. 
RESULTS 
After extensive quality control (Methods), serum levels of SHBG, total testosterone and 
estradiol were available in up to 425,097 individuals with genetic data in UK Biobank (UKBB) 
(Table S1). We additionally estimated bioavailable (free/unbound) testosterone in 382,988 
individuals (Methods). Genetic association testing was performed in European ancestry 
individuals and within each sex for the four traits, using a linear mixed model to control for 
relatedness and population structure. We identified a heritable component for all traits except 
estradiol levels in women (h2g=1.6% (s.e 1%) (Table 1). As the majority (78%) of women had 
estradiol levels below the limit of detection (as expected, given most women in UKBB are post-
menopausal), analysis of this trait was limited by low sample numbers and a bias towards 
detecting age at menopause-associated loci. Therefore, assessment of estradiol levels in 
women was not considered further.  
To identify independent genetic determinants for sex hormone measures, we next performed 
distance-based clumping and approximate conditional analysis (Methods). In total, we 
identified 2,571 genome-wide significant trait-signal pairs (Tables S2-S11). These trait-signal 
pairs ranged from 22 signals for estradiol in men, to 658 for SHBG in a sex-combined analysis. 
To validate these findings, we performed replication using three available datasets (Methods) - 
a previously published GWAS meta-analysis of SHBG levels in 21,791 individuals19, 9,138 
individuals with testosterone measurements from the EPIC-Norfolk study and published data 
on 2,913 individuals from the Twins UK study with nine sex hormones measured20. Whilst these 
studies were substantially smaller than UK Biobank, we found strong directional consistency 
with our results. Assessment of our SHBG-associated loci in the published meta-analysis (Figure 
ED1) demonstrated 236/278 (85%, binomial P=6.1x10-34) of the captured male SHBG signals had 
consistent direction of effect (77 with P<0.05), compared to 241/283 in women (85%, binomial 
P=4.2x10-35, 60 at P<0.05). In Twins UK, all identified genome-wide significant variants in 
aggregate were significantly associated and directionally concordant for the respective sex 
hormone traits (Table S12). Finally, in the EPIC-Norfolk study we estimated the magnitude of 
effect a genetic risk score for SHBG and testosterone had on the respective trait levels (Figure 
ED2). Men with the 5% highest genetic risk have 0.69 [0.53-0.85 95%CI] and 1.27 [1.12-1.41] 
standard deviation (equivalent to 2.55 nmol/L and 21.34 nmol/L) higher total testosterone and 
SHBG respectively than men with the 5% lowest scores; the equivalent difference in women is 
0.45 [0.26-0.64] SDs (0.28 nmol/L) and 1.29 [1.12-1.45] (35.91 nmol/L) respectively. 
To putatively map each identified variant to its effector gene, we first identified any non-
synonymous variant highly correlated (r2>0.7) with a lead index variant. This implicated one or 
more genes at 482/2571 (19%) SNP-trait pairs, highlighting 291 unique genes (Tables S2-S11). 
To identify the likely tissue(s) and cell type(s) of action for sex hormone-associated loci, we 
integrated our data with gene expression data across 53 tissues available from the GTeX 
consortium using LD score regression (Methods). In both sexes, liver was the most enriched 
tissue (Figure ED3), consistent with its established role as the site of SHBG production. Skeletal 
muscle in men and adrenal gland in women were the next strongest enriched tissues. In 
contrast to findings for other reproductive traits, we found no evidence for enrichment of gene 
expression in any brain cell type (Figure ED3). Within the three prioritised tissue types (liver, 
skeletal muscle and adrenal gland), we identified 161 unique eQTL-linked genes mapping within 
300kb to 200/2571 SNP-trait pairs (Methods, Tables S2-S11). We note that further evidence 
from experimental studies is needed to confirm our putative genes, but the current findings 
should help to guide such work. 
Distinct genetic architectures of testosterone regulation between sexes 
Despite similar heritability estimates (Table 1), the genetic component to variation in circulating 
testosterone levels was very different between sexes, as indicated by null genome-wide 
correlations between sexes (Table 1) and limited overlap of genome-wide significant signals 
between sexes (Tables S13-14). This discordance was partly due to opposing effects between 
sexes at several individual loci, rather than solely null associations in one sex. For example, of 
the 254 signals for total testosterone in women, 72 were also at least nominally associated 
(P<0.05) with total testosterone in men; however, of these, 33 (46%) showed directionally-
opposing effects between sexes (Table S7). Notably, several variants had genome-wide 
significant but directionally-opposing effects on testosterone in men and women (Table S5), 
including the missense variants: rs56196860 in FKBP4 which encodes a regulator of androgen 
receptor transactivation activity21; and rs28929474 in SERPINA1 which encodes one of a family 
of proteins which are reported to regulate steroidogenesis in testicular Leydig cells22.  
Several other signals showed sex-specific effects (Table S5). Notably, 7 of 9 X-chromosome 
signals for total testosterone in men and women combined altered levels only in men, including 
five variants located in/near genes associated with androgen insensitivity (AR), 
hypogonadotropic hypogonadism (ANOS1), failure of sex steroid 11 beta-hydroxylation 
(HPRT1), disrupted steroidogenesis (STARD8), and hypospadias (DGKK) (Table S5). Notable 
autosomal male-specific testosterone signals were located at key regulators of puberty timing 
(e.g. LIN28B-rs7759938; TACR3-rs528845403 and KISS1-rs201416723) and androgen secretion 
(NR0B2-rs182050989 or biosynthesis (SRD5A2-rs113017476) (Table S5). 
Among many signals with apparent female-specific effects on testosterone were five signals 
in/near to genes encoding enzymes in the cytochrome P450 family with reported roles in 
testosterone hydroxylation (CYP3A7-rs45446698, CYP2D6-rs5751229, CYP2C8/CYP2C9-
rs11572082, CYP11B2-rs6471583 and POR-rs17853284) (Table S5). Other signals with female-
specific effects on testosterone included: reported PCOS susceptibility loci at FSHB 
(rs12294104) and THADA (rs58839393); CYP17A1 (rs11441374) encoding 17,20-lyase, the 
decisive step in androgen synthesis, and its critical cofactor CYB5A-rs17089026/rs79384925); 
and also near genes encoding luteinizing hormone subunit beta (LHB-rs78248023) and 
hormone receptors for glucocorticoids (NR3C1-rs34632394) and prolactin (PRLR-rs112694713) 
(Table S5). 
In contrast to testosterone traits, the genetic architecture of SHBG levels was highly concordant 
between men and women (rg 0.84 [0.81-0.87], P<1x10-100) (Table 1); 315 (88%) of the 359 
genome-wide significant variants in women were also at least nominally associated (P<0.05) 
with SHBG in men (Table S4).   
Genetic overlap between sex hormone traits within sexes. 
Among men, we found partially overlapping genetic determinants between the different sex 
hormone traits. This was reflected by positive genetic correlations between all four sex 
hormone measures (Table 1, rg 0.19-0.73), with the exception of a weak negative correlation 
between SHBG and bioavailable testosterone (rg -0.048 (SE 0.024), P=0.04).  These genetic 
correlations were very similar to the observed phenotypic correlations (Table S15). In contrast 
to men, among women, there was a weak negative genetic correlation between total 
testosterone and SHBG (rg= -0.06 in women; 0.73 in men), a strong negative correlation 
between bioavailable testosterone and SHBG (-0.74 in women; -0.05 in men) and a similar 
positive correlation between total and bioavailable testosterone (0.65 in women; 0.60 in men), 
again closely reflecting the observed phenotypic correlations (Table 1, Table S15).  
Cluster analysis identifies loci with primary SHBG or testosterone effects 
Testosterone levels are dependent on SHBG levels but genetic variants may allow us to 
separate distinct components of variation in sex hormone levels. To identify signals with 
primary effects on individual sex hormone traits, we performed a cluster analysis of all 525 
signals that reached genome-wide significance for one or more sex hormone measure in men, 
identifying 3 clusters (Figure 1, Table S16). The largest cluster (362 signals) was characterised 
by loci with relatively strong positive associations with SHBG; in combination, SNPs in this 
cluster also increased total testosterone, reduced bioavailable testosterone and increased 
estradiol in men (Table S17). Hence, this cluster (termed “male SHBG cluster”, Methods) 
represents a genetic instrument with primary SHBG-increasing effects, and secondary divergent 
effects on total (higher) and bioavailable testosterone (lower) that are consistent with the 
known hormone-regulatory role of SHBG. 
Among men, the second identified cluster (122 loci) was consistently associated with higher 
total and bioavailable testosterone levels in a dose-response manner.  In combination, SNPs in 
this cluster also increased estradiol levels, but had no effect on SHBG (P=0.66) (Table S17). 
Hence, this cluster (termed “male specific testosterone cluster”) represents a genetic 
instrument with primary (total and bioavailable) testosterone-increasing effects, with 
secondary estradiol-increasing effects (consistent with the physiological conversion of 
androgens to estrogens), but independent of SHBG.  
Among men, a third small cluster (14 signals) strongly increased estradiol, but not other sex 
hormone measures (Table S17). The most prominent signal in this cluster (rs781858752) was 
uniquely associated with estradiol in men (P=7.6x10-15) but not with any other sex hormone 
measure in men or women (all P>0.05), and influenced expression of IGHV3-9 and IGHV1-8 in 
the liver (Table S11).  
In addition to separating testosterone from SHBG effects, defining such clusters is an important 
step for downstream analyses to minimise the pleiotropic effects of SNPs that may have much 
stronger effects on other sex hormones. For example, the apparent strong male estradiol 
association (P=1.5x10-35) at the X-chromosome rs111386834 locus, ~200kb from KAL1, is clearly 
secondary to a stronger effect of this signal on bioavailable (P=3x10-670) and total testosterone 
(P=1.5x10-372), consistent with the known role of this gene on the hypothalamic-pituitary 
reproductive axis. 
As in men, in women, cluster analysis of all 614 signals for any of the three sex hormone 
measures in women (Figure 2) identified two main clusters, representing genetic instruments 
with i) primary SHBG effects and secondary directionally-opposing effects on total and 
bioavailable testosterone (“female SHBG cluster”, 373 signals) and ii) consistent testosterone 
effects but no aggregate effect on SHBG (“female specific testosterone cluster”, 241 signals) 
(Table S18). Hence, in both men and women, cluster analyses resulted in genetic instruments 
that allowed us to test specific testosterone-increasing effects, independent of SHBG. 
Understanding the impact of sex hormone measures on disease outcomes 
Having identified over 2500 associations between genetic variants and sex hormone measures, 
we designed a set of Mendelian randomization (MR) analyses (Methods) to inform the causal 
effects of sex hormones on two broad categories of disease outcomes – a) Type 2 diabetes 
(T2D), insulin resistance, body composition and related metabolic disease risk factors, and b) 
hormone sensitive cancers. Given the lack of overlap between men and women in sex hormone 
associated variants (Table 1, Tables S13-14), and the possible different metabolic effects of 
these hormones between sexes, we focused analyses on sex-specific disease outcomes.  As 
exposures, we tested total and bioavailable testosterone and SHBG in both men and women, 
and also estradiol in men. For each outcome trait, we identified the largest published sex-
specific GWAS meta-analysis with publicly available data (Table S19). We then performed a 
series of MR analyses using two-sample inverse variance-weighted (IVW), Egger and weighted 
median models (Methods). We additionally modelled different genetic risk scores by i) Steiger 
filtering to exclude variants with larger effects on metabolic traits than the tested sex hormone, 
ii) cluster filtering using variants in the above defined clusters representing primary effects on 
SHBG or testosterone independent of SHBG. To further inform the role of SHBG, we additionally 
tested the 2 cis variants in SHBG as an instrument for SHBG.    
Using these genetic instruments, in men and women separately, we could infer causal positive 
effects of testosterone levels on lean body mass and number of lifetime sexual partners (Tables 
S20-S22, Figure ED4). These findings are consistent with the established positive effects of 
testosterone on these traits in randomised controlled trials6 and therefore support the validity 
of our genetic instrument analyses.  
Mendelian randomization analyses in men 
In men, we found evidence of beneficial effects of higher testosterone on metabolic traits 
(Figure 3, Figure ED4-5, Tables S20 and S23). For T2D and related traits, the evidence of a 
protective effect of testosterone was most consistent when using the cluster-specific genetic 
instrument representing a primary (total and bioavailable) testosterone-increasing effect 
independent of SHBG. Using data from 34,990 men with T2D and 150,760 male controls23, and 
67,506 non diabetic men with fasting glucose levels available24, exposure to higher 
testosterone, independent of SHBG, conferred lower T2D risk and lower fasting glucose: each 1-
SD higher testosterone level (approximately 3.7 nmol/L) was associated with a 15% lower T2D 
risk in men (total testosterone odds ratio (OR): 0.85; 95% CI: 0.77, 0.95; cluster-specific 
testosterone OR: 0.86; 95% CI 0.76,0.98). These metabolically beneficial associations were 
directionally consistent, but did not reach nominal significance (p<0.05), in all sensitivity 
analyses (Tables S20, S24; Figure ED5).  
In contrast to these apparent beneficial metabolic effects, MR analyses indicated that 
testosterone increases prostate cancer risk in men: each 1-SD higher bioavailable testosterone 
level increased prostate cancer risk by 23% (OR: 1.23; 95%CI 1.13-1.33), with consistent findings 
across all testosterone genetic instruments (unfiltered, Steiger-filtered and cluster-filtered) 
(Figure 4, Table S25, Figure ED6). 
We found no compelling evidence for an effect of estradiol in men on any metabolic or body 
composition trait, however, confidence intervals were wide (Tables S20, S23 and S25).  
Mendelian randomization analyses in women.  
Despite evidence for a positive effect of total testosterone on lean body mass in women as well 
as men, testosterone was associated with several adverse metabolic outcomes in women 
(Table S21).  
We found consistent evidence supporting a causal effect of testosterone on higher PCOS risk in 
women. These effects were most evident with bioavailable testosterone, with positive findings 
across all MR models and all instruments (unfiltered, Steiger-filtered and cluster-filtered) 
(Figure ED7-8, Table S21). These effects equated to an odds ratio of 1.51 (95%CI 1.33-1.72) per 
1-SD higher bioavailable testosterone. 
MR analyses also showed a causal effect of bioavailable testosterone on higher T2D risk and 
higher fasting insulin in women (using unfiltered and Steiger-filtered instruments) (Table S21, 
Figures ED4 and ED9). Risk of T2D was increased by 37% (OR: 1.37; 95% CI 1.22, 1.53) per 1-SD 
higher bioavailable testosterone. We also found evidence for protective effects of SHBG on T2D 
across all MR models using Steiger-filtered and cluster-filtered instruments, and apparent 
protective effects of SHBG on fasting insulin levels, and central fat measures, android and 
visceral, but not total body fat, (consistently across unfiltered, Steiger-filtered and cluster-
filtered instruments) (Tables S21 and S26, Figures ED4 and ED9). These effects equated to an 
odds ratio for T2D of 0.65 (95%CI: 0.58-0.72) per 1-SD (approximately 30.3 nmol/L) higher 
SHBG. The lack of association with the testosterone-specific cluster (representing higher 
testosterone independent of SHBG) on T2D or fasting insulin (Table S21), indicates that the 
above associations with bioavailable testosterone and SHBG in women might be driven by 
direct effects of SHBG, however, we did not have a genetic instrument that was specific to 
SHBG.  
We found evidence that testosterone increased the risk of estrogen receptor (ER)+ but not ER- 
breast cancer, with consistent findings across all MR models and instruments (Figure ED6, Table 
S27). Furthermore, testosterone increased the risk of endometrial cancer but reduced the risk 
of ovarian cancer, again with consistent findings across sensitivity models (Figure ED6, Table 
S27). There was also evidence for a protective effect of SHBG on risk of endometrial cancer in 
women, which was consistent across all models, but a risk-increasing effect of SHBG on ER- 
breast cancer.  
cis variants in the SHBG gene provide a confirmatory test of higher circulating SHBG levels, 
independent of potential confounding by adiposity and insulin resistance, but including effects 
of reciprocally lower bioavailable testosterone. Results using two cis variants were generally 
consistent with our main analyses (Table S24), with consistent associations with the low 
frequency missense SHBG variant on PCOS and T2D in women, and directionally-consistent but 
smaller effects of the common non-coding variant.  
Discussion 
We identify >2500 genetic variant sex-hormone associations and provide insights into the 
genetic architecture of sex hormone regulation and its relevance to disease. We see limited 
overlap between the genetic variants identified in men and women for all sex hormone traits 
except SHBG, and even overlapping signals often showed divergent effects. Cluster analyses 
across all identified variants distinguished, in each sex, groups of variants with testosterone-
increasing effects either dependent or independent of SHBG. These clusters helped inform 
genetic causal inference analyses by showing primary metabolic effects of testosterone that 
were beneficial in men (lower fasting glucose and lower T2D risk) but harmful in women (higher 
PCOS risk). In contrast, associations that are seen only with bioavailable testosterone and SHBG 
(e.g. T2D in women) could be driven by effects of SHBG, directly or in combination with 
testosterone. 
Testosterone Trials in men, the largest RCTs of testosterone administration to date, found clear 
benefits of testosterone on sexual function and body composition in men, but insufficient data 
on disease outcomes due to sparse numbers of such outcomes even in the largest trials. While 
RCT evidence remains the gold standard, genetic instrumental variable analyses provide a more 
robust evidence base than phenotypic observational study designs, as they are less prone to 
confounding and reverse causality. For example, while adverse effects of testosterone on 
prostate cancer risk might be expected, given the established role of testosterone-reducing 
agents in the treatment of prostate cancer, the evidence from observational studies is 
remarkably diverse: out of 45 papers, 18 reported positive associations between testosterone 
and prostate cancer, 17 reported negative associations and 10 reported no association8. 
Furthermore, in a recent analysis of 20 prospective studies, low bioavailable testosterone 
predicted lower risk of low-grade prostate cancers but higher risk of high-grade cancers9. 
Therefore, our findings advance our understanding of the risks and benefits of this widely used 
therapy in men.  
Our findings that higher testosterone increases the risk of PCOS in women is important in 
demonstrating the aetiological role of testosterone in this common disorder, rather than simply 
being a consequence of upstream defects in ovarian dysfunction and insulin signalling. 
Androgen-blocking agents are widely used to treat symptoms of hyperandrogenism in women 
with PCOS, but evidence is lacking for the role of androgens in the aetiology and prevention of 
this condition25. Similarly, experimental evidence of the effects of testosterone administration 
in women arises from several RCTs, albeit using substantially lower doses than in men and 
often topical routes of administration, which substantiate the positive effects of testosterone 
on the primary outcome, sexual function. However, even in combination, these RCTs include 
insufficient disease events to inform about its potential effects on cardio-metabolic traits and 
cancer risks26.  
Our findings positively link testosterone to number of sexual partners and lean body mass in 
men and women, which provide reassurance about the validity of our approach. However, 
some limitations need to be acknowledged. While we could distinguish a cluster-specific 
genetic instrument for testosterone that was independent of SHBG, the effects of this, and our 
other testosterone instruments, might be mediated at least in part by downstream conversion 
of testosterone to estradiol. This has been hypothesized to explain the observed phenotypic 
associations between testosterone and higher risk of ER-positive breast cancer. However, 
regardless of downstream mechanisms, our findings provide evidence to inform the 
consequences of real-world differences in testosterone on health outcomes. Similarly, while 
our SHBG-related clusters in men and women were not independent of testosterone, and 
therefore cannot inform the debate about SHBG-specific metabolic effects, they reflect the 
actual downstream biological effects of SHBG on (higher) total testosterone and (lower) 
bioavailable testosterone. A second limitation, common to all MR analyses, is that genetic 
instruments represent lifelong exposures to the risk factor, and so may have different effects to 
short-medium term pharmacological interventions even if they achieve the same difference in 
circulating concentrations. A third limitation is that the discovery of genetic variants was 
performed in a single large study that is known to be enriched for healthier and older 
individuals, potentially influencing (likely underestimating) the effect size of associated variants. 
Finally, the MR approach depends on some key assumptions which we attempted to assess 
using a range of sensitivity analyses. Associations across these sensitivity analyses were 
generally directionally consistent, but did not always reach p<0.05. We note that our findings 
do not preclude an additional bi-directional effect of disease status on testosterone or suggest 
that other factors are not important causal determinants of the tested outcomes. 
Our study highlights three important methodological considerations. First, in light of the 
substantial overlap between genetic determinants of testosterone and SHBG within each sex, 
our cluster-based analyses allowed us to identify subsets of variants that alter testosterone 
independent of SHBG. This effectively removes potential direct biological effects of SHBG and 
its confounding effects on adiposity and insulin resistance27. Second, we used Steiger filtering of 
our genetic instruments, to exclude variants with stronger effects on metabolic traits compared 
to their effects on sex hormones. This approach helped reduce the possibility of reverse 
causality, an issue that is increasingly important in large-scale GWAS28. 
Finally, our findings show the importance of sex-specific analyses, both in the discovery of 
genetic variants for sex hormone traits and in the analyses of downstream traits.  The 
apparently sex-divergent effects of testosterone on T2D were obfuscated by sex-combined 
data. Available large-scale sex-specific data on T2D was invaluable for our study - unfortunately 
similar sex-specific data for cardiovascular disease are not yet available, which will be critically 
important to understand the wider cardio-metabolic impact of testosterone. Hence, while the 
findings relating to adverse metabolic effects of testosterone in women may inform clinical 
practice, it is premature to infer wider beneficial metabolic effects in men.  
In conclusion, our findings provide unique insights into the disease impacts of testosterone and 
highlight the importance of sex-specific analyses of disease risk. 
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Tables and Figures 
Table 1. Heritability of and genetic correlations between sex hormone traits included in the 
genome-wide association analyses. 
Figure 1 | Cluster analysis of male identified sex hormone signals. All Z-score effects are aligned 
to the male total testosterone increasing allele. 
Figure 2 | Cluster analysis of female identified sex hormone signals. All Z-score effects are 
aligned to the female bioavailable testosterone increasing allele. 
 
 
Figure 3. Plots showing the odds of T2D and PCOS per unit higher testosterone and SHBG 
using genetic instruments in Mendelian Randomization analyses. Unit measurements for the 
individually transformed exposure traits can be found in Table S1. Specific testosterone refers 




Figure 4. Plot showing the odds of cancer per unit higher testosterone and SHBG using genetic 
instruments in Mendelian Randomization analyses. Unit measurements for the individually 
transformed exposure traits can be found in Table S1. Specific testosterone refers to a total 
testosterone score which has no aggregate effect on SHBG. 
 
 
BCAC breast = breast cancer; BCAC ER- = Breast cancer, ER negative subtype; BCAC ER+ = Breast 






Phenotype preparation in UK Biobank 
Discovery analyses were performed in the full UK Biobank study which has been described 
extensively elsewhere29. All UK Biobank participants provided written informed consent, the 
study was approved by the National Research Ethics Service Committee North West–Haydock 
and all study procedures were performed in accordance with the World Medical Association 
Declaration of Helsinki ethical principles for medical research. At baseline a panel of 34 
biomarkers were measured across the full ~500,000 study participants. We selected three sex 
hormone traits - SHBG, testosterone and estradiol - and additionally calculated a measure of 
bioavailable testosterone using the Vermeulen equation30,31. Individual trait transformations 
and exclusion criteria are detailed in Supplementary Table S1. 
Genetic discovery analysis 
We used genetic data from the “v3” release of UK Biobank29, containing the full set of HRC and 
1000G imputed variants. In addition to the quality control metrics performed centrally by UK 
Biobank, we defined a subset of “white European” ancestry samples using a K-means clustering 
approach applied to the first four principal components calculated from genome-wide SNP 
genotypes.  Individuals clustered into this group who self-identified by questionnaire as being 
of an ancestry other than white European were excluded. After application of QC criteria, a 
maximum of 425,097 UK Biobank participants were available for analysis with genotype and 
phenotype data. Association testing was performed using a linear mixed models implemented 
in BOLT-LMM32 to account for cryptic population structure and relatedness. Only autosomal 
genetic variants which were common (MAF>1%), passed QC in all 106 batches and were 
present on both genotyping arrays were included in the genetic relationship matrix (GRM). 
Across each of the four sex hormone traits we performed GWAS discovery analyses both within 
and across sexes, with the exception of estradiol where analyses were performed only in men. 
To help improve reproducibility of results, analyses were conducted independently at two sites 
and compared for consistency, with any discrepancies investigated. A decision on which dataset 
to use for each discovery GWAS was made based on strength of association of the previously 
reported SHBG gene locus variants19. 
Genotyping chip, age at baseline and 10 genetically derived principal components were 
included as covariates in all models, in addition to specific covariates used for individual traits 
detailed in Supplementary Table S1. For SHBG we included body mass index as a covariate 
which was previously demonstrated to increase statistical power by reducing trait variance. To 
avoid any effects which may be attributed to collider bias33, we compared BMI adjusted 
estimates to BMI unadjusted estimates across all identified genome-wide significant SHBG 
signals. We discarded from further consideration any loci which changed effect direction 
between models and/or had large changes in effect estimate and statistical significance. For 
downstream analyses, genetic loci from the BMI adjusted analyses were used with 
corresponding effect estimates from the BMI unadjusted analyses. 
Replication was performed using three independent datasets. Firstly, a previously published 
CHARGE consortium meta-analysis of SHBG (age and BMI adjusted) in 21,791 individuals (9,390 
women, 12,401 men)19. Given these data used HapMap 2 imputation, we found proxy HapMap 
2 variants with a minimum r2>0.5 to align (Supplementary Table S28). Secondly, a previously 
published GWAS of 2,913 individuals from the Twins UK resource20 with measured 
dehydroepiandrosterone (DHEAS), total testosterone, follicle stimulating hormone (FSH), 
luteinizing hormone (LH), estradiol, progesterone, prolactin and SHBG and calculated free 
androgen index. Finally, replication of the genetic scores was attempted with measurements of 
total testosterone (5,334 men and 3,804 women) and of SHBG (5,694 men and 5,476 women) 
from the EPIC Norfolk study34. Here, regression models were conducted on ventiles of the 
score, and were controlled for 10 genetic principal components, and additionally menopausal 
status in women (Figure ED2). Given the relatively small sizes of these replication studies, we 
used these data to validate genetic instruments in aggregate rather than as individual loci 
(Supplementary Table S28). 
Signal selection and genetic instrument generation 
We defined statistically independent signals (described as lead or index variants) using 1Mb 
distanced-based clumping across all imputed variants with P<5x10-8, an imputation quality 
score > 0.5 and MAF > 0.1%. Although several studies have suggested other p-value thresholds 
for genome-wide significance more stringent (e.g P<6x10-9) than the currently accepted 
community standard (P<5x10-8), as our primary focus of this paper was the production of 
genetic risk scores (rather than focus on individual genetic variants), we felt the more liberal 
threshold was acceptable to help maximise variance explained. We note that multiple trait 
correction would likely be over-conservative given the correlation structure between traits. 
Genome-wide significant lead variants that shared any correlation with each other due to long 
range linkage disequilibrium (r2>0.05) were excluded from further consideration. These loci 
were additionally augmented using approximate conditional analyses implemented in GCTA35. 
Here, secondary signals were only considered if they were a) uncorrelated (r2<0.05) with a 
previously identified index variant b) genome-wide significant pre and post conditional analysis, 
c) had an effect estimate which did not change by more than 10% between models. 
For downstream analyses we produced genetic instruments using two approaches. Firstly, we 
considered only SNPs that were genome-wide significant (and defined using clumping method 
above) for a given trait and sex to derive 7 genetic instruments: 
1) “SHBG-Men” (N=357) - Individually genome-wide significant SNPs for SHBG in men, 
discovered using BMI adjusted analysis but using weights from a BMI unadjusted 
analysis 
2) “SHBG-Women” (N=359) - As above, but in women. 
3) “Total T-Men” (N=231) - Individually genome-wide significant SNPs for total 
testosterone in men, weighted by individual SNP beta estimate for total testosterone 
4) “Total T-Women” (N=254) - As above, but in women. 
5) “Bioavailable T - Men” (N=125) - Individually genome-wide significant SNPs for 
bioavailable testosterone in men, weighted by individual SNP beta estimate for 
bioavailable testosterone 
6) “Bioavailable T - Women” (N=180) - As above, but in women 
7) “Estradiol-Men” (N=22) - Individually genome-wide significant SNPs for estradiol in men, 
weighted by individual SNP beta estimates for estradiol 
Secondly, given the genetic overlap between traits, we observed that some signals were shared 
between sex hormone traits but appeared to have much stronger effects in one versus others. 
To help derive additional genetic risk scores that reflected this, we took all genome-wide 
significant signals within each sex but across traits, and performed ward-based hierachical 
clustering36 on individual variant Z-scores. We used the observed clusters from these analyses 
to produce give additional genetic instruments (Supplementary Table S16): 
8) A “Male SHBG cluster” (N=362), formed from SNPs with dominant effects on SHBG in 
men. Each SNP in this genetic instrument is weighted by its effect from the BMI 
unadjusted SHBG analysis. 
9) A “Male testosterone cluster” (N=122), formed from SNPs with dominant effects on 
both total and bioavailable testosterone in men. Each SNP in this genetic instrument is 
weighted by its effect on total testosterone. 
10) A “Male estradiol cluster” (N=14), formed from SNPs with dominant effects on estradiol 
in men. 
11) A “Female SHBG cluster” (N=373), formed from SNPs with dominant effects on SHBG in 
women. Each SNP in this genetic instrument is weighted by its effect from the BMI 
unadjusted SHBG analysis. 
12) A “Female testosterone cluster” (N=241), formed from SNPs with dominant effects on 
both total and bioavailable testosterone in women. Each SNP in this genetic instrument 
is weighted by its effect on total testosterone. 
Gene prioritization 
We used the SMR software package37 to systematically map associated genetic variants to 
genes via expression effects (eQTLs). For all analyses we included expression data from liver, in 
addition to skeletal muscle in men and adrenal gland in women. All expression data was 
generated by the GTEx consortium (v7), made available from the SMR website resource section 
(https://cnsgenomics.com/software/smr/#DataResource). Only genes passing multiple test 
correction and exhibiting no statistically significant evidence of coincidental eQTL overlap 
(assessed by the SMR HEIDI metric) were considered. The same data was additionally used to 
perform global tissue enrichment using LDSC-SEG38. 
Mendelian randomization analyses 
For outcome traits, we limited analyses to traits that i) were previously reported as associated 
with circulating sex hormone levels, ii) have sex specific associations with sex hormones, and iii) 
where sex-specific GWAS data was available in large non-UK Biobank studies (see 
Supplementary Table S19). Given the potential for bias in MR studies when a large proportion 
of genetic variants are discovered in the same sample as the outcome is measured, we used 
non UK Biobank GWAS data as the primary outcome data. This resulted in us considering as an 
outcome six diseases: type 2 diabetes, PCOS, prostate cancer, breast cancer, ovarian cancer and 
endometrial cancer; two glycaemic traits: fasting insulin as a measure of insulin resistance and 
fasting glucose; and four main measures of body composition: BMI, waist hip ratio adjusted for 
BMI, and, using DEXA measures, total body fat and total lean mass. Where we observed 
positive associations for total fat or lean mass, we tested 6 more specific measures of body 
composition; android fat, gynoid fat, android lean mass, gynoid lean mass, subcutaneous and 
visceral fat from DEXA data.  
Each of the 12 genetic instruments described above was used as an exposure instrumental 
variable in our subsequent Mendelian Randomization analyses. Where a signal was not present 
in the outcome GWAS, we identified a 1000 Genomes or HapMap proxy with r2>0.5 within 
250kb either side of the signal and their relevant weight was included in our genetic instrument 
(Supplementary Table S28).  
In each MR test we assessed a number of widely used methods -  inverse variance weighted 
(IVW), weighted median, and MR-Egger39,40.  Mendelian randomisation relies on some key 
assumptions. These assumptions include 1) that alleles are randomly assigned among people; 
and 2) that alleles that influence exposure do not influence the outcome via any other pathway 
other than through the exposure. The use of the most robust models available (linear mixed 
models), as implemented in BOLT-LMM, to ensure alleles are not stratified within the UK 
Biobank provides reassurances that the first assumption holds. To address the second 
assumption, we performed several additional analyses. We used two additional MR methods 
(MR-Egger and Median MR) both of which are more robust to pleiotropy – directionally 
consistent results strengthened our causal inference. We used the MR-Egger intercept, with a p 
value of p<0.05, to provide evidence that pleiotropy could be affecting the MR results. 
Furthermore, we implemented an approach known as “Steiger filtering”. In this test, we 
excluded variants with larger effects on outcome traits or traits known to be closely associated 
to outcome traits compared to their effects on the sex hormone exposure trait41. Given the 
strong association between SHBG and adiposity and insulin resistance, and the large discovery 
sample size, it was possible that many variants could be associated with sex hormone levels via 
an outcome trait, rather than having direct effects on sex hormones, so invalidating the MR 
assumptions. We excluded between 2 and 40 % of variants (depending on the sex hormone) 
trait if they had larger effects (based on an absolute standardized beta) on any one of 11 
metabolic traits available in the UK Biobank (fasting glucose, T2D, coronary artery disease, HDL-
C, LDL-C, triglycerides, total-cholesterol, diastolic and systolic blood pressure, BMI and Waist 
hip ratio adjusted for BMI). A full table of which variants were excluded and why is given in 
Supplementary Table S29). 
Secondly, we considered only cis variants at the SHBG gene locus (Supplementary Table S24). 
Here we used two variants in low linkage disequilibrium as more specific but less powerful 
genetic instruments. Variants in cis with a gene likely represent the most specific test of the 
causal role of a circulating protein encoded by that gene. One of these variants (rs1799941) is 
common and has been used in several previous MR studies of SHBG16,19, whilst the other 
(rs6258) is rare (~1% MAF) and alters SHBG’s binding affinity for testosterone. 
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